Amarenco P - Search Results

1

Global Prospective Safety Analysis of Rivaroxaban.

Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, Hess S, Camm AJ; Global XANTUS program Investigators. Kirchhof P, et al. Among authors: amarenco p. J Am Coll Cardiol. 2018 Jul 10;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058. J Am Coll Cardiol. 2018. PMID: 29976287 Free article.

2

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.

Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ. Boekholdt SM, et al. Among authors: amarenco p. J Am Coll Cardiol. 2014 Aug 5;64(5):485-94. doi: 10.1016/j.jacc.2014.02.615. J Am Coll Cardiol. 2014. PMID: 25082583 Free PMC article. Review.

3

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, van Eickels M, Turpie AG. Camm AJ, et al. Among authors: amarenco p. Vasc Health Risk Manag. 2014 Jul 17;10:425-34. doi: 10.2147/VHRM.S63298. eCollection 2014. Vasc Health Risk Manag. 2014. PMID: 25083135 Free PMC article. Clinical Trial.

4

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG; XANTUS Investigators. Camm AJ, et al. Among authors: amarenco p. Eur Heart J. 2016 Apr 7;37(14):1145-53. doi: 10.1093/eurheartj/ehv466. Epub 2015 Sep 1. Eur Heart J. 2016. PMID: 26330425 Free PMC article.

5

Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy.

Coleman CI, Haas S, Turpie AG, Kuhls S, Hess S, Evers T, Amarenco P, Kirchhof P, Camm AJ; XANTUS Investigators. Coleman CI, et al. Among authors: amarenco p. Clin Cardiol. 2016 Oct;39(10):565-569. doi: 10.1002/clc.22565. Epub 2016 Jun 30. Clin Cardiol. 2016. PMID: 27362695 Free PMC article. Clinical Trial.

6

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.

Camm AJ, Turpie AGG, Hess S, Amarenco P, Lambelet M, Haas S, van Eickels M, Kirchhof P; XANTUS Investigators. Camm AJ, et al. Among authors: amarenco p. Europace. 2018 Jun 1;20(6):e87-e95. doi: 10.1093/europace/eux127. Europace. 2018. PMID: 29016755

7

Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG. Camm AJ, et al. Among authors: amarenco p. Europace. 2019 Mar 1;21(3):421-427. doi: 10.1093/europace/euy160. Europace. 2019. PMID: 30052894

8

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.

Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ. Amarenco P, et al. Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):70-79. doi: 10.1093/ehjcvp/pvy041. Eur Heart J Cardiovasc Pharmacother. 2019. PMID: 30423165

9

Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.

Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, Lavados P, Mundl H, Bornstein N, Meseguer E, Amarenco P, Cucchiara B, Camps-Renom P, Makaritsis K, Korompoki E, Papavasileiou V, Marti-Fabregas J, Milionis H, Vemmos K, Connolly SJ, Hart RG; NAVIGATE ESUS Investigators. Ntaios G, et al. Among authors: amarenco p. Stroke. 2019 Sep;50(9):2477-2485. doi: 10.1161/STROKEAHA.119.025168. Epub 2019 Aug 12. Stroke. 2019. PMID: 31401971 Clinical Trial.

10

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban.

Kirchhof P, Haas S, Amarenco P, Hess S, Lambelet M, van Eickels M, Turpie AGG, Camm AJ; XANTUS Investigators*. Kirchhof P, et al. Among authors: amarenco p. J Am Heart Assoc. 2020 Mar 3;9(5):e009530. doi: 10.1161/JAHA.118.009530. Epub 2020 Feb 21. J Am Heart Assoc. 2020. PMID: 32079476 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

479 results

Search Page